Single‐nucleotide polymorphisms are associated with cognitive decline at Alzheimer's disease conversion within mild cognitive impairment patients
Abstract
The growing public threat of Alzheimer's disease (AD) has raised the urgency to quantify the degree of cognitive decline during the conversion process of mild cognitive impairment (MCI) to AD and its underlying genetic pathway. The aim of this article was to test genetic common variants associated with accelerated cognitive decline after the conversion of MCI to AD.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2017
- Source ID
- 10.1016/j.dadm.2017.04.004
Entities
People
- Andrew J. Saykin
- Dehan Kong
- Eunjee Lee
- Fengchang Xie
- Hongtu Zhu
- Joseph G. Ibrahim
- Kelly S. Giovanello
- Liuqing Yang
- P. Murali Doraiswamy
- The Alzheimer’s Disease Neuroimaging Initiative*
- Yue Wang
Organizations
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Canadian Institutes of Health Research
- Cancer Prevention and Research Institute of Texas
- Chiron Corporation
- Duke University
- Eli Lilly and Company
- GE HealthCare
- Indiana University
- Laboratoires Servier
- Merck & Co.
- Nanjing Normal University
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- University of Michigan
- University of North Carolina at Chapel Hill
- University of Texas at Austin
- University of Toronto